Drugs / BAY79-4620
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01065623 | Apr → Aug 2010 | neoplasm | Bayer | Terminated | No outcome recorded |
| Phase 1 | NCT01028755 | Nov 2009 → Apr 2013 | neoplasm | Bayer | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BAY79-4620 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01065623 ↗ |
| Route | Intravenous | “BAY79-4620 will be administered as 1 hour IV infusion” NCT01028755 ↗ |